Stockreport

Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million [Yahoo! Finance]

Zevra Therapeutics, Inc.  (ZVRA) 
PDF focused on providing therapies for people living with rare disease, today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) f [Read more]